Home
HelpTest Code 1DIS Human Leukocyte Antigens (HLA) A-B-C Disease Association Typing Low Resolution, Blood
Specimen Required
Container/Tube: Yellow top (ACD solution A or B)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood in original tube. Do not aliquot.
Additional Information: Specimen acceptability is based on extracted DNA concentration and not sample age.
Forms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Secondary ID
609354Useful For
Determining class I human leukocyte antigens (HLA) on specimens for those patients who have become refractory to platelet transfusions and identify potential disease associations or markers for drug hypersensitivity
Method Name
Polymerase Chain Reaction (PCR)/Next-Generation Sequencing (NGS)
Reporting Name
HLA-A-B-C DisAssoc Typing LowRes,BSpecimen Type
Whole Blood ACDSpecimen Minimum Volume
3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood ACD | Ambient (preferred) | ||
| Refrigerated | |||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Human leukocyte antigens (HLA) are regulators of the immune response. HLA class I typing is used to identify HLA-matched platelets for alloimmunized refractory patients and identify presence of HLA antigens associated with a number of diseases or as drug hypersensitivity markers Class I HLA antigens include A, B, and C loci. This assay is designed to provide low-to-medium resolution for HLA class I typing (A, B, C). Low-to-medium resolution defines the typing at the antigen level (first field). This contrasts with high-resolution typing, which defines typing at the allele (molecular) level (second field or higher).
Reference Values
Not applicable
Interpretation
Interpretation depends on the rationale for ordering the test.
Cautions
No significant cautionary statements
Clinical Reference
1. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki K. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978;69(2):103-120
2. Colinas RJ, Bellisario R, Pass KA. Multiplexed genotyping of beta-globin variants from PCR-amplified newborn blood spot DNA by hybridization with allele-specific oligodeoxynucleotides coupled to an array of fluorescent microspheres. Clin Chem. 2000;46(7):996-998
3. Kennedy AE, Ozbek U, Dorak MT. What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017;44(5):195-211. doi:10.1111/iji.12332
4. Caillat-Zucman S. New insights into the understanding of MHC associations with immune-mediated disorders. HLA. 2017;89(1):3-13. doi: 10.1111/tan.12947
5. Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41(1):1-12. doi:10.1111/iji.12088
6. Profaizer T, Pole A, Monds C, Delgado JC, Lazar-Molnar E. Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol. 2020;81(7):354-360
Method Description
Next-generation sequencing is used to type for Class I alleles (A, B, and C) from genomic DNA. This method uses strictly controlled polymerase chain reaction (PCR) conditions for DNA amplification. The PCR amplicons are processed and sequenced via the Illumina MiSeq instrument. The output files are analyzed in provided software, which compares the data against the IMGT/HLA database to assign the molecular typing.(Package inserts: Holotype HLA Kit. Omixon; v3.0.1, 08/16/2019; NGSgo HLA Kit. GenDx; v2, 02/2021)
For resolution of an allelic ambiguity or in select cases, the following additional methodologies may be utilized:
-Sequence-based typing (SBT) by Sanger sequencing(Package insert: SeCore Sequencing and GSSP Kits. One Lambda, Inc; Rev 3, 02/06/2021)
-SBT by sequence-specific primers (SSP)(Package insert: Olerup SSP HLA typing kits including Taq Polymerase. CareDx; Rev 04, 12/2020)
-Reverse sequence-specific oligonucleotides (SSO)(Package insert: LABType SSO Typing Test. One Lambda, Inc.; Rev 04, 11/11/2019)
Day(s) Performed
Monday, Thursday
Report Available
7 to 17 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81372
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 1DIS | HLA-A-B-C DisAssoc Typing LowRes,B | 96629-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 1DA02 | ABC DisAssoc Comment | 96625-9 |
| 1DA03 | A - 1 Equivalent | 13298-5 |
| 1DA04 | A - 2 Equivalent | 13298-5 |
| 1DA05 | A - 1 Molecular | 78014-8 |
| 1DA06 | A - 2 Molecular | 78014-8 |
| 1DA07 | B - 1 Equivalent | 13299-3 |
| 1DA08 | B - 2 Equivalent | 13299-3 |
| 1DA09 | B - 1 Molecular | 78015-5 |
| 1DA10 | B - 2 Molecular | 78015-5 |
| 1DA11 | Bw - 1 Equivalent | 96633-3 |
| 1DA12 | Bw - 2 Equivalent | 96633-3 |
| 1DA13 | C - 1 Equivalent | 13302-5 |
| 1DA14 | C - 2 Equivalent | 13302-5 |
| 1DA15 | C - 1 Molecular | 96636-6 |
| 1DA16 | C - 2 Molecular | 96636-6 |
| LRTM1 | Test Method | 85069-3 |